IQVIA Shares Rise After Q1 Revenue Beats Expectations on AI, Pharma Demand

IQVIA Holdings Inc. (IQV) shares rose to $174.26 from $160.94 before its first-quarter earnings report, after the company posted stronger-than-expected revenue growth and solid execution across its Commercial Solutions and R&D Solutions segments. Management said demand improved across core offerings, particularly analytics and artificial intelligence-related services. CEO Ari Bousbib said organic revenue growth in Commercial Solutions doubled from a year earlier, while organic revenue growth in R&D Solutions tripled. Patient Solutions, Analytics and Consulting were cited as key areas of momentum. Investors will watch how quickly AI products scale with major pharmaceutical clients, how backlog and large multiyear contracts convert into revenue, and whether IQVIA can manage margin pressure from currency movements and business mix. Biotech funding trends and client R&D pipelines remain key indicators for future performance.